More MS news articles for January 2000

Antigenics Announces Issuance of Patent Covering Treatment of Autoimmune Diseases with Heat Shock Proteins

Tuesday January 4, 8:02 am Eastern Time

Company Press Release

SOURCE: Antigenics, L.L.C.

NEW YORK, Jan. 4 /PRNewswire/ -- Antigenics, L.L.C. announced today the issuance of a patent with broad claims covering methods of treatment of autoimmune diseases, such as type 1 diabetes and multiple sclerosis, with heat shock proteins. The patent is the ninth issued in the US for which Antigenics has exclusive worldwide rights.

``The issuance of this patent is an important milestone because it covers our third major therapeutic application of heat shock proteins, following on the heels of patent issuances in the areas of cancer and infectious diseases,'' said Garo H. Armen, Ph.D., Antigenics' Chairman and CEO.

The company's lead product candidate for treatment of autoimmune diseases is the heat shock protein gp96, which has demonstrated efficacy in animal models of type 1 diabetes and multiple sclerosis. Antigenics has also made progress in elucidating the mechanism by which heat shock proteins modulate the immune system to treat these diseases.

US patent No. 6,007,821 is owned by Fordham University and is entitled, ``Method and Compositions for the Treatment of Autoimmune Disease Using Heat Shock Proteins.''

Antigenics is engaged in the discovery and development of a family of novel immunotherapeutic drugs for the treatment of life threatening and chronic medical conditions. The company's immunotherapeutics are based on a specific class of proteins known as heat shock proteins and their ability to modulate the immune system. Antigenics is currently evaluating its lead immunotherapeutic, Oncophage®, in six clinical trials for the treatment of four different cancers, and the company anticipates starting its first pivotal clinical trial by mid-2000. Antigenics is also developing immunotherapeutics to treat infectious diseases, such as genital herpes, and autoimmune diseases, such as diabetes and multiple sclerosis. Based upon Antigenics' scientific and drug development skills, its technology platform and strategic expertise, the company plans to establish a leadership position in drug discovery, development and commercialization.

This release is also available on the Internet at http://www.antigenics.com.

SOURCE: Antigenics, L.L.C.